Tradestie Institutional Equity Comparison Engine
ANRO vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANRO Overall Edge
ANRO Captures Institutional Edge (3โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, ANRO sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
ANRO N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner
ANRO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -62.7%
Momentum & Technical Winner
ANRO
1Y +105.7% vs -73.8% ยท 52W Pos 53% vs 14%
Options & Structure Winner
ANRO
BREAKDOWN (9th %ile IV) vs BREAKDOWN (N/A IV)
ANRO
NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$24.91
-8.15% 1D
Market Cap
$1.2B
1M Return
+9.16%
1Y Return
+105.7%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 15.0
Fund 38.0
Flow 64.0
Mom 40.0
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap
$22.5M
1M Return
+12.12%
1Y Return
-73.76%
Forward P/E
23.0x
Unified AI Score
43.5 / 100
HOLD
Tech 23.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ANRO +105.7%
CVM -73.76%
Spread: +177.75 pp (ANRO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ANRO TTM Op. Margin: 0.0%
CVM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs CVM. Trailing 12-month operating profitability (ANRO 0.0% vs CVM 0.0%) and valuation multiples (ANRO N/M vs CVM 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANRO | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.2B | $22.5M | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | +0.0% | -62.7% | Higher Growth | ANRO |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -46.7% | -252.5% | Higher ROE | ANRO |
| 52-Week Range Position Momentum | 53% ($11โ$37) | 14% ($1โ$8) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 2.03ฮฒ ยท 94% Vol | 0.42ฮฒ ยท 140% Vol | Lower Realized Risk | ANRO |
| Unified Institutional Score Composite Signal | 34.3 / 100 (SELL) | 43.5 / 100 (HOLD) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ANRO vs CVM Buy Guide
ANRO
BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
CVM
BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ANRO nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.